No registrations found.
ID
Source
Brief title
Health condition
IBD, Crohn's disease
Sponsors and support
Intervention
Outcome measures
Primary outcome
Proportion of patients with clinical remission after 4 weeks of dietary intervention. Clinical remission will be defined as a Harvey Bradshaw Index (HBI) < 5.
Secondary outcome
- Proportion of patients with clinical response. Clinical response will be defined as HBI reduction ≥ 3.
- Feasibility; proportion of patients that have maintained the diet throughout the trial period, combined with the compliance. Feasibility will be defined as >70% adherence to the protocol (based on known drug adherence rates in this study group, which is 66%). Compliance to the diet will be assessed by serum (pro)-albumin, urea and retinol binding protein.
- Proportion of patients with biochemical remission. Biochemical remission will be defined as CRP ≤10 mg/L and a faecal calprotectin 200≤g/g.
- Proportion of patients with relapse of CD (necessitating surgery, (re)introducing biologics, corticosteroids or IS).
- Changes in bristol stool scale
- Changes in grip strength
- Changes in % fat, % free fat mass, fat mass in kg, free fat mass in kg, body mass, body volume and body density as measured by BOD POD- Qualify of life measured by IBDQ
- Safety and tolerability of the low caloric low protein diet will be assessed by VAS scores by PROM: PRO-2 (abdominal pain and stool frequency). and adverse events.
Molecular markers:
- Changes in CRP and faecal calprotectin (FCP)
- Changes in molecular factors (leptin, HO-1, GST, H2S) and microbiome.
Background summary
Many patients with inflammatory bowel disease (including Crohn’s disease and Ulcerative Colitis) associate dietary components with disease activity. Although several dietary interventions have been investigated for the treatment of Crohn’s disease (CD), study results have been mixed. At the Erasmus MC, Department of Surgery, an integrated calorie and protein restriction (CRPR) diet has been developed. This diet was shown to be safe and feasible in healthy kidney donors and morbidly obese patients for five consecutive days prior to surgery (METC number 2012-134). The CRPR diet is now being tested in metastatic colorectal cancer patients receiving irinotecan, to optimize anti-tumor effects and survival (METC number 15-710). In mouse models, the CRPR diet results in a reduction of acute and chronic pro-inflammatory responses, including a reduction of inflammatory mTOR signaling in a leptin-dependent manner, and reduction of IL6 and TNFα levels. As these inflammatory responses play a pathogenic role in IBD, a CRPR diet may also be effective for treatment in IBD. In addition, diets are known to modulate the microbiome, and as dysbiosis of the intestinal microbiota is also assumed to contribute to CD pathology, we speculate that modulation of the microbiome through the CRPR diet is another mechanism of action potentially contributing to the induction of remission in CD.
This study will investigate a calorie restriction/protein restriction (CRPR) diet, consisting of 70% of the individual’s required calories and ~20% of the individual’s protein requirement, based on basal metabolic rates and on the daily energy requirements. An induction phase will consist of 4 days diet at week 1, 3 days at week 2, 3 days at week 3 and 3 days at week 4. CD patients with endoscopically mild to moderate disease will be included. Patients will be randomized 1:1 to either dietary intervention or budesonide 9mg induction therapy for four weeks. The dietary intervention will consist of 4 days diet at week 1, 3 days at week 2, 3 days at week 3 and 3 days at week 4. Clinical efficacy of CRPR diet for induction of remission will be assessed after these four weeks. Blood and stool samples will be collected for molecular and microbial (microbiome) analysis.
Study objective
To assess the efficacy of a calorie and protein restricted (CRPR) diet for induction of remission in CD.
Study design
baseline, week 2, week 4
Intervention
The CRPR diet consists of an estimated 70% of the individuals required calories and 20% of the individuals protein (12), based on the basal metabolic rates and on the daily energy requirements (DER) as calculated with the Harris-Benedict equation (14) and with the BODPOD (the Gold Standard Body Composition Tracking System is an air displacement plethysmograph which uses whole-body densitometry to determine body composition (fat and fat-free mass) in adults (18, 19)l. The Harris-Benedict equation takes into account sex, height, age, body weight and estimated activity level. Normal protein intake is set at 20% of the total calories based on the DER. To facilitate the dietary requirements, participants will receive calorie- and protein-restricted powder shakes (Scandishake® Mix) as the main component of the diet, which can be supplemented with a limited amount of protein-restricted products (mainly fruits and vegetables) until the desired individual energy content of the diet is reached.
Inclusion criteria
- Crohn's disease
- Active mild to moderate disease (defined as an endoscopic SES-CD score ≥ 6 or in case of exclusive ileal disease ≥ 4, after ileocoecal resection a Rutgeert's score >i2 and a HBI score between 5 and 10)
- Age between 18 ¨C 70 years at baseline
Exclusion criteria
- BMI: <18.5, >35
- Weight loss of >5% within one month or >10% within 6 months prior to the study
- Use of pro- and antibiotics in 6 weeks prior to start of the study
- Known allergy/intolerance to any of the ingredients in the diets
- Known malignancy or dysplasia
- Pregnancy, lactation
-Risk of malnutrition as determined by renal insufficiency, renal or electrolyte abnormality (serum creatinine >2x upper limit of normal (ULN); eGFR < 30 mL/min Serum potassium outside the 3,5- 5,0 mmol/l range and serum sodium outside the 135-145 mmol/l range)
- Presence of toxins or other signs of infectious agents in stool sample
(i.e. clostridium, salmonella, shigella, yersinia or campylobacter)
- Insulin-dependent diabetes mellitus
- Patients using oxygen and not able to stop for 30 minutes
Design
Recruitment
Followed up by the following (possibly more current) registration
No registrations found.
Other (possibly less up-to-date) registrations in this register
No registrations found.
In other registers
Register | ID |
---|---|
NTR-new | NL7418 |
NTR-old | NTR7651 |
Other | : METC NL60259.078.16 |